The aberrant activation of STAT5 has been implicated in various types of cancer. In normal cells, STAT5 activity is tightly regulated; however, in cancer cells, it is often constitutively activated, leading to uncontrolled cell growth and resistance to apoptosis. This makes STAT5 a critical factor in oncogenesis. For instance, in hematological malignancies such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), persistent STAT5 activation is a hallmark feature.
